日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Follow-Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural-ODE Approaches

肿瘤动态建模中的随访偏差:经典方法与神经常微分方程方法的比较

Turner, David C; Laurie, Mark; Li, Shuhui; Ngo, Huy X; Li, Chunze; Jin, Jin Y; Lu, James; Brooks, Logan

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

一种提高莫苏妥珠单抗治疗复发或难治性滤泡性淋巴瘤获益风险比的新型递增剂量方案

Li, Chi-Chung; Bender, Brendan; Wilkins, Justin; Li, Feifei; Turner, David C; Wang, Bei; Deng, Rong; Vadhavkar, Shweta; Li, Zao; Kwan, Antonia; Huang, Huang; Peng, Kun; Penuel, Elicia; Huw, Ling-Yuh; Chanu, Pascal; Li, Chunze; Yin, Shen; Wei, Michael C

Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes

肿瘤剂量优化:针对不同分子类型的个体化方法

Zhu, Jiawen; Schroeder, Amy; Frank, Sabine; Boetsch, Christophe; Jamois, Candice; Kassir, Nastya; Korfi, Koorosh; Punnoose, Elizabeth; Vaze, Anjali; Trask, Peter; Gosai, Pritti; Fridlyand, Jane; Li, Chunze

IUC24392-85 Real-world use of erdafitinib in urothelial carcinoma: an Italian multicenter retrospective study

IUC24392-85 厄达替尼在尿路上皮癌中的真实世界应用:一项意大利多中心回顾性研究

Brooks, Logan; Dolton, Michael; Langenhorst, Jurgen; Yoshida, Kenta; Lien, Yi Ting Kayla; Malhi, Vikram; Li, Chunze; Perez-Moreno, Pablo; Bond, John; Chen, Ya-Chi; Yu, Jiajie; Dri, A; Polymeropoulos, A; Lai, E; Pierantoni, F; Ghidini, M; Mennitto, A; Zivi, A; Tassinari, E; Cengarle, R; Fratino, L

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

莫苏妥珠单抗在中国复发或难治性滤泡性淋巴瘤患者中的药代动力学和药效学的种族敏感性评估

Li Junyi, Liao Michael Z, Wilkins Justin, Penuel Elicia, Wang Bei, Vadhavkar Shweta, Peng Kun, Cao Junning, Li Zhiming, Zhang Ye, Li Wenjin, Li Donghang, Zhou Mingzhu, Wei Michael C, Kwan Antonia, Zhao Rong, Li Chunze, Li Chi-Chung, Turner David C

Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling

利用基于生理的药代动力学模型评估莫苏妥珠单抗通过细胞因子(IL-6)升高介导的CYP3A药物相互作用

Chen, Yuan; Ma, Fang; Jones, Nicholas; Deng, Rong; Li, Chunze; Li, Chi-Chung

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

来自 POLARIX 研究的 polatuzumab vedotin 在既往未接受治疗的弥漫性大B细胞淋巴瘤 (DLBCL) 患者中的群体药代动力学和暴露-反应分析

Deng, Rong; Gibiansky, Leonid; Lu, Tong; Flowers, Christopher R; Sehn, Laurie H; Liu, Qi; Agarwal, Priya; Liao, Michael Z; Dere, Randall; Lee, Calvin; Man, Gabriel; Hirata, Jamie; Li, Chunze; Miles, Dale

Patient, industry, and regulatory perspective on antibody-drug conjugates dose optimization

患者、行业和监管机构对抗体药物偶联物剂量优化的看法

Hamed, Salaheldin; Li, Chunze; Liao, Michael Z; Warwick, Lorna; Zhou, Zhu

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma

莫苏妥珠单抗在复发/难治性B细胞非霍奇金淋巴瘤中的群体药代动力学和CD20结合动力学

Bender, Brendan; Li, Chi-Chung; Marchand, Mathilde; Turner, David C; Li, Feifei; Vadhavkar, Shweta; Wang, Bei; Deng, Rong; Lu, James; Jin, Jin; Li, Chunze; Yin, Shen; Wei, Michael; Chanu, Pascal

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

基于肿瘤动力学模型的Ib/II期联合治疗研究决策支持:基于III期研究IMpower150重采样的回顾性评估

Bruno, René; Marchand, Mathilde; Yoshida, Kenta; Chan, Phyllis; Li, Haocheng; Zou, Wei; Mercier, Francois; Chanu, Pascal; Wu, Benjamin; Lee, Anthony; Li, Chunze; Jin, Jin Y; Maitland, Michael L; Reck, Martin; Socinski, Mark A